Discover the story of Epitopea, a biotechnology company specializing in immunotherapy, born from a research project supported by CQDM.
Based in Montréal and Cambridge (UK), Epitopea is developing next‑generation therapeutic vaccines. Their goal: to train the immune system to precisely recognize and target tumor‑specific antigens, opening up new possibilities in cancer treatment.
From the earliest stages, CQDM’s strategic support played a decisive role. By backing the project at an early phase, CQDM helped accelerate scientific progress and reach key milestones toward technology validation.
Today, Epitopea is emerging as a promising player in personalized immunotherapy.
